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Background: Epithelial-mesenchymal transition (EMT) has been believed to be related with chemotherapy resistance
in non-small cell lung cancer (NSCLC). Recent studies have suggested eIF5A-2 may function as a proliferation-related
oncogene in tumorigenic processes.
Methods: We used cell viability assays, western blotting, immunofluorescence, transwell-matrigel invasion assay,
wound-healing assay combined with GC7 (a novel eIF5A-2 inhibitor) treatment or siRNA interference to investigate the
role of eIF5A-2 playing in NSCLC chemotherapy.
Results: We found low concentrations of GC7 have little effect on NSCLC viability, but could enhance cisplatin
cytotoxicity in NSCLC cells. GC7 also could reverse mesenchymal phenotype in NCI-H1299 and prevented A549 cells
undergoing EMT after TGF-β1 inducement. eIF5A-2 knockdown resulted in EMT inhibition.
Conclusion: Our data indicated GC7 enhances cisplatin cytotoxicity and prevents the EMT in NSCLC cells by inhibiting
eIF5A-2.
Keywords: N1-guanyl-1, 7-diaminoheptane (GC7), Eukaryotic translation initiation factor 5A2 (eIF5A-2), Epithelial-
mesenchymal transition (EMT), Cisplatin, Non-small cell lung cancer (NSCLC)Background
Lung cancer is the leading cause of cancer deaths world-
wide with non-small cell lung cancer (NSCLC) account-
ing for approximately 80% of all lung cancer diagnoses
[1]. Although surgery is the first choice of treatment,
chemotherapy is necessary in most cases in order to im-
prove the therapeutic effect; however, despite many
novel chemotherapy regimens and molecular targeted
therapies, its pathogenesis is yet to be fully understood,
and the prognosis remains poor [2-4].
Epithelial-mesenchymal transition (EMT) is a com-
plex, reversible process which induces epithelial cells to* Correspondence: guofengshaolihuili@163.com
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unless otherwise stated.transform to mesenchymal phenotype [5]. These lead to
a loss of epithelial characteristics including cell-cell junc-
tions, polarity and epithelial markers, e.g., E-cadherin;
and a gain of mesenchymal properties, including stronger
migration and invasion capabilities [6] and mesenchymal
markers, e.g., vimentin and fibronectin [7]. Although many
reports have demonstrated that EMT is involved in drug
resistance in NSCLC [8-12], the mechanism is unclear; as
such, determining an effective method to inhibit EMT in
NSCLC could significantly improve treatment regimes.
Eukaryotic initiation factor (eIF5A) is the the only
cellular protein that contains the unusual amino acid
hypusine [Ne-(4-amino-2-hydroxybutyl) lysine].It has
two isoforms: eIF5A-1 and eIF5A-2. Study demon-
strated that accumulating evidence links eIF5A to cell
proliferation, cancer progression, invasiveness, metastasis
and poor clinical prognosis and the post-translationalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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potentiation of the activity of anti-cancer agents [13,14].
eIF5A-2 is located on chromosome 3q26, a region fre-
quently amplified in several types of tumors [15]. It is es-
sential for maintaining cell proliferation [16,17] and
inhibition of eIF5A-2 has been shown to suppress cell pro-
liferation in many tumors [18,19]. As a result, it has been
suggested that eIF5A-2 may function as a proliferation-
related oncogene in tumorigenic processes [20].
Several studies have found that N1-guanyl-1,7-diami-
noheptane (GC7) suppresses tumor cell proliferation by
inhibiting eIF5A-2 [21,22]. In this study, we aimed to in-
vestigate the chemotherapeutic effect of GC7 in NSCLC
and determine whether eIF5A-2 mediates EMT and in-
creases chemosensitivity in NSCLC controls.Methods
Cell lines and cell culture
The human NSCLC cell lines, A549 and NCI-H1299, were
purchased from the American Type Culture Collection
(ATCC; Manassas, VA, USA) and stored following ATCC
guidelines. All cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS;
Gibco, Carlsbad, CA, USA) and 1% penicillin-streptomycin
(Sigma-Aldrich, St. Louis, MO, USA). The cells were main-
tained at 37°C in a humidified atmosphere of 5% CO2.eIF5A-2 siRNA transfection
NSCLC cells were transfected with eIF5A-2 siRNA
(10 μmol/mL; Santa Cruz Biotechnology, Dallas, TX, USA)
or negative control siRNA (Invitrogen) using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. The transfection medium was replaced with culture
medium 6 h after transfection. All subsequent experiments
were performed 24 h after transfection and repeated in
triplicate.CCK-8 cell viability assay
A Cell Counting Kit-8 (CCK8; Dojindo, Kumamoto, Japan)
was used to measure relative cell viability after treatment.
NSCLC cells (5 × 103 cells/well) were seeded into 96-well
plates and cultured for 24 h. The culture medium was re-
placed by medium containing the required concentrations
of cisplatin or cisplatin combined with GC7, and the cells
were incubated for 48 h. CCK-8 solution (10 μL/well) was
added, the cells were incubated for a further 4 h, and ab-
sorbance was measured at 450 nm using an MRX II micro-
plate reader (Dynex Technologies, Chantilly, VA, USA).
Relative cell viability was calculated as a percentage of un-
treated controls.Western blot analysis
The cells were washed twice in ice-cold phosphate buffer
solution (PBS) and resuspended in 100 μL cell lysis buf-
fer (Cell Signaling, Danvers, MA, USA) with protease
inhibitors (Sigma-Aldrich). The protein concentrations
were quantified using a BCA Protein Kit (Thermo
Fisher, Rockford, IL, USA). Cell lysates (40 μg/lane)
were separated by 10% SDS-PAGE, transferred to polyvi-
nyl diflouride (PVDF) membranes (Millipore, Billerica,
MA, USA) and blocked with Tris-buffered saline (TBS)
containing 0.1% Tween 20 (TBST) and 5% bovine serum
albumin (BSA). The membranes were incubated with anti-
E-cadherin, anti-Vimentin (Biovision, Milpitas, CA, USA)
or anti-eIF5A-2 (Proteintech, Chicago, IL, USA) anti-
bodies (1:1000) at 4°C overnight, washed three times
with TBST and then incubated with the appropriate
HRP-conjugated secondary antibodies for 1 h at room
temperature. The protein bands were developed by chemi-
luminescence (GE Healthcare, Piscataway, NJ, USA) and
visualized by autoradiography on X-Ray films (Kodak,
Rochester, NY, USA). Band densities were estimated using
Image-Pro Plus v. 6.0 software (Media Cybernetics,
Bethesda, MD, USA) and protein levels were normal-
ized to GAPDH.
Immunofluorescence
Cells were washed with ice-cold PBS, fixed in 4% parafor-
maldehyde for 30 min followed by incubation with 3%
H2O2 for 15 min at 37°C and blocked in fetal calf serum for
a further 15 min. After incubation with anti-E-cadherin,
anti-vimentin or anti-eIF5A-2 antibodies (1:1,000) over-
night at 4°C, the cells were washed with ice-cold PBS
and incubated for 1 h at room temperature with the ap-
propriate secondary antibodies (1:2000; GE Healthcare):
goat anti-mouse FITC-conjugated secondary antibody
(E-cadherin) or goat anti-mouse Cy5-conjugated sec-
ondary antibody (vimentin). Nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) and
the cells were observed by fluorescence confocal micros-
copy (Olympus, Japan).
Wound-healing assay
Cells were seeded into six-well plates at a density of 2 × 105
cells/well and cultured with RPMI-1640 medium con-
taining 10% FBS overnight at 37°C in a humidified at-
mosphere of 5% CO2, after which, the medium was
changed to RPMI-1640 without FBS and the cells were
cultured for a further 24 h until >90% confluence. The
cells were harvested by scraping the adherent cells
using a plastic 100 μL tip. After transfection with eIF5A-2
siRNA (10 μmol/mL) or treatment with N1-guanyl-1,7-
diaminoheptane (GC7; 20 μM) for 6 h, the cells were
treated with transforming growth factor-β1 (TGF-β1) at
a concentration of 10 ng/mL for 24 h at 37°C in a
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taken using an inverted phase contrast microscope
(Olympus; magnification, 40×) at 0 h and 24 h. The ra-
tio of the remaining wound area relative to the initial
wound area was calculated and the wound area was
quantified using Image-Pro Plus v. 6.0 software.
Transwell-matrigel invasion assay
After transfection with eIF5A-2 siRNA (10 μmol/mL) or
treatment with GC7 (20 μM) for 6 h, the cells were
treated with TGF-β1 (10 ng/mL) for 48 h. The cells were
seeded at a density of 5 × 104 cells/well in the upper
chamber of a Transwell 24-insert plate with RPMI-1640
medium. The upper chambers were coated with Matrigel
(BD Biosciences, San Jose, CA, USA) and the lower
chamber contained RPMI-1640 plus 10% FBS medium.
After 24 h, the bottom of the inserts were fixed in
methanol for 10 min and stained with hematoxylin and
eosin (H&E). The cells that had invaded to the lower surface
were measured using an inverted phase contrast microscope
(Olympus; magnification, 40×) and photographed.
Statistical analyses
Data were analyzed using GraphPad Prism 5 software
(GraphPad, San Diego, CA, USA) using one-way analysis
of variance (ANOVA) followed by Tukey post-hoc test.
Results are presented as mean ± SEM; P <0.05 was con-
sidered statistically significant.
Results
Low concentrations of GC7 had little cytotoxicity against
NSCLC cells
Western blot analysis was used to determine eIF5A-2 pro-
tein expression in A549 and NCI-H1299 cells. The results
showed that eIF5A-2 was expressed in the control cells of
both cell lines; however expression was higher in NCI-
H1299 cells compared to A549 cells (Figure 1A). In order
to test the cytotoxicity of GC7 in A549 and NCI-H1299
NSCLC cell lines CCK-8 cell viability assays were per-
formed. The results showed that GC7 had almost no effectFigure 1 Low concentrations of GC7 had little cytotoxicity against NS
and NCI-1299 cells. (B,C) Low concentrations of GC7 have little effect on ceon A549 cell viability between 0 and 20 μM, and NCI-
H1299 cell viability was well when GC7 concentrations
were less than 30 μM, indicating that GC7 had little
cytotoxicity against NSCLC cells at low concentrations
(Figure 1B,C). Conversely, at GC7 concentrations ex-
ceeding 30 μM in A549 cells or exceeding 40 μM in
NCI-H1299 cells, cell viability was significantly inhib-
ited (Figure 1B,C). Some studies have reported that low
concentrations of GC7 (10 μM) could inhibit the hypu-
sination of eIF5A2 effectively in some tumor cells
[15,19]. In this case, the 20 μM concentration GC7,
which has been showed had little cytotoxicity against
NSCLC cells but could inhibit the eIF5A2 activation,
was chosen for further co-treatments with cisplatin.
GC7 enhanced cisplatin sensitivity of mesenchymal
NSCLC cells; epithelial NSCLC cells showed greatest
sensitivity to cisplatin
CCK-8 assays were carried out to assess the dose-
dependence of A549 (epithelial phenotype) and NCI-H1299
(mesenchymal phenotype) cell viability to cisplatin treat-
ment. The results found that increasing doses of cisplatin
reduced cell viability in both cell lines (Figure 2A): the IC50
values at 72 h were 3.069 μg/mL (2.735–3.402 μg/mL)
and 7.140 μg/mL (6.432–7.848 μg/mL) in A549 and NCI-
H1299 cells, respectively (Table 1), showing that A549
cells exhibited higher sensitivity to cisplatin than NCI-
H1299 cells. When cisplatin was combined with GC7
treatment (20 μM), cisplatin sensitivity increased in
both cell lines compared to cisplatin treatment alone:
IC50 values at 72 h decreased to 4.454 μg/mL (3.848–
5.060 μg/mL; P <0.0001) in NCI-H1299 (Figure 2B) and
2.360 μg/mL (2.098–2.622 μg/mL; P <0.01) in A549
cells (Figure 2C, In Additional file 1), indicating that
GC7 increased cisplatin sensitivity most markedly in
NCI-H1299 cells.
The difference between phenotypes was examined by
western blotting and immunofluorescence to detect ex-
pression of E-cadherin (epithelial) and vimentin (mesen-
chymal) EMT markers in both NSCLC cell lines. TheCLC cells. (A) Western blotting showing eIF5A-2 expression in A549
ll viability.
Figure 2 GC7 enhanced cisplatin sensitivity of mesenchymal NSCLC cells; epithelial NSCLC cells showed greatest sensitivity to cisplatin.
(A–C) GC7 enhances NSCLC cell sensitivity to cisplatin. (D–E) A549 and NCI-H1299 express different levels of EMT marker proteins, E-cadherin
and vimentin.
Table 1 IC50 values for cisplatin in NSCLC cell lines with





Cisplatin Cisplatin + GC7 (20 μM)
A549 3.069 (2.735–3.402) 2.360 (2.098–2.622)**
NCI-H1299 7.140 (6.432–7.848) 4.454 (3.848–5.060)****
▲IC50 concentrations of cisplatin [μg/mL; mean (95% CI)].
**P <0.05 vs. cisplatin alone.
****P <0.0001 vs. cisplatin alone.
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to cisplatin, showed higher expression of the epithelial
marker E-cadherin, but no expression of the mesenchymal
marker vimentin. In contrast, NCI-H1299 showed higher
expression of the mesenchymal marker vimentin, but no ex-
pression of the epithelial marker E-cadherin (Figure 2D,E).
GC7 enhanced cisplatin sensitivity in NSCLC cells via
inhibition of eIF5A-2
GC7 can inhibit the activity of eIF5A-2 (In Additional
file 2). In order to discover the mechanism by which
Figure 3 GC7 enhanced cisplatin sensitivity in NSCLC cells via inhibition of eIF5A-2. (A) eIF5A-2 siRNA inhibits eIF5A-2 in both A549 and
NCI-H1299 cells. (B–C) Comparing changes in cisplatin sensitivity in A549 and NCI-H1299 NSCLC cells after treatment with eIF5A-2 siRNA alone or
combined with GC7.
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eIF5A-2 siRNA into A549 and NCI-H1299 cells to inter-
fere with eIF5A-2 expression, and found that eIF5A-2
expression was significantly inhibited in both NSCLC
cell lines (Figure 3A). We then treated these transfected
cells with cisplatin alone, or cisplatin combined with
GC7, and carried out CCK-8 cell viability assays. With-
out GC7, NCI-H1299 cells were the most sensitive to
cisplatin after eIF5A-2 siRNA transfection: the IC50 at
72 h was 4.468 μg/mL (4.093–4.842 μg/mL; Table 2). Al-
though A549 cells remained sensitive to cisplatin, the
IC50 value was lower: 2.626 μg/mL (2.466–2.785 μg/mL;
P = 0.0145 vs. cisplatin alone. Table 2). In contrast, when
cisplatin treatment was combined with GC7 after eIF5A-
2 siRNA transfection, there was little change in the cis-
platin sensitivity of both cell lines: the IC50 values at
72 h were 3.982 μg/mL (3.609–4.356 μg/mL; P = 0.0648)
and 2.434 μg/mL (2.307–2.560 μg/mL; P =0.0571) in
NCI-H1299 and A549 cells, respectively (Table 2;
Figure 3B,C). As GC7 also inhibits eIF5A-1’s activity,
we evaluated the role of eIF5A-1 in this process. Western
Blot analysis indicated that eIF5A-1 was expressed in the
control cells of both cell lines; however the expression of
eIF5A-1 was higher in NCI-H1299 cells compared to
A549 cells. Moreover, We also evaluated the effect of
eIF5A-1 in the siRNA transfected cell. The results showed
that when cisplatin treatment was combined with GC7
after eIF5A-1 siRNA transfection, there was little change
in the cisplatin sensitivity of both cell lines (In Additional
file 3).
GC7 regulated EMT in NSCLC cells via inhibition of
eIF5A-2
Having established that GC7 enhanced the chemothera-
peutic effect of cisplatin in NCI-H1299 more than in
A549 cells, we wished to determine whether the mech-
anism was related to EMT. After GC7 treatment for
72 h, A549 cells retained their epithelial characteristics
(Figure 4A,B), whereas NCI-H1299 cells displayed a loss
of mesenchymal properties and a gain of epithelial
properties, appearing a reduction in their migration
and invasion capabilities (Figure 4E,F). Furthermore,
the NCI-H1299 cells showed increased levels of epithe-
lial marker E-cadherin and lower levels of mesenchymal
marker vimentin (Figure 4C,D).Table 2 IC50 values for cisplatin in NSCLC lines with or





siRNA + Cisplatin siRNA + Cisplatin + GC7 (20 μM)
A549 2.626 (2.466–2.785) 2.434 (2.307–2.560)
NCI-H1299 4.468 (4.093–4.842) 3.982 (3.609–4.356)
▲IC50 values indicate the cisplatin concentration [μg/mL; mean (95% CI)].Several reports have shown that TGF-β1 could induce
epithelial NSCLC cells to undergo EMT. In this study,
TGF-β1 exposure (10 ng/mL for 48 h) transformed epi-
thelial A549 cells to mesenchymal phenotype, causing
the cells to develop an elongated appearance, irregular
pseudopodia, weaker cell-cell junctions (Figure 5A) and
stronger migration and invasion capabilities compared
to control cells (Figure 5D,E). In addition, the cells showed
lower levels of epithelial marker E-cadherin and increased
levels of mesenchymal marker vimentin (Figure 5B,C).
Conversely, if the A549 cells were pre-treated with GC7
before exposure to TGF-β1, the cells retained their epithe-
lial appearance, levels of EMT markers, and migration and
invasion capabilities (Figure 5A–E).
In order to verify whether eIF5A-2 was a key factor in
GC7 regulation of EMT, we transfected eIF5A-2 siRNA
into NCI-H1299 cells without carrying out GC7 treat-
ment. The results showed that the transfected NCI-
H1299 cells transformed from mesenchymal phenotype
to epithelial phenotype (Figure 6A–D). Conversely, when
the transfected cells were treated with GC7, the cells
stayed as epithelial phenotype (Figure 6A–D).
Discussion
EIF5A-2 is a member of the eukaryotic initiation factor
family. It is located on chromosome 3q26, a region fre-
quently amplified in several tumors, and is highly expressed
in tumors such as colorectal cancer [23], ovarian cancer
[24] and bladder cancer [25]. Overexpression of eIF5A-2
has been reported to enhance invasion and metastasis in
malignancies [20,26], for example, He et al. reported that
overexpression of eIF5A-2 was correlated with invasion in
NSCLC and was a poor prognostic marker of NSCLC [20].
In addition, eIF5A has been shown to induce EMT in hepa-
tocellular carcinoma [26] and colorectal carcinoma [27].
Many studies have shown that EMT is related to car-
cinogenicity, metastasis and poor prognosis in many
tumors including NSCLC [28-31], and it has been sug-
gested that EMT is involved in drug resistance in
NSCLC [10-12]. During EMT, epithelial markers such
as E-cadherin decrease, while mesenchymal markers
such as vimentin increase [8]. In our study, we showed that
NCI-H1299 cells, a mesenchymal phenotype, expressed
higher levels of eIF5A-2. In contrast A549 cells, an epithe-
lial phenotype, expressed lower levels of eIF5A-2. Further-
more, we showed that epithelial A549 cells were more
sensitive to cisplatin, whereas the mesenchymal NCI-
H1299 cells were related to drug resistance.
Several studies have reported that GC7 possesses antitu-
mor properties [32,33] and significantly suppresses tumor
cell proliferation [21,22]. The enzymes deoxyhypusine syn-
thase (DHS) and deoxyhypusine hydroxylase (DOHH) are
required to catalyze the post-translational modifications
which lead to the activation of eIF5A2 [33]. GC7 is a
Figure 4 GC7 regulated EMT in NSCLC cells via inhibition of eIF5A-2. (A–B) Western blotting and immunofluorescence showed no significant
changes in expression levels of EMT marker proteins, E-cadherin and vimentin, are observed in A549 cells after GC7 treatmen. (C-D) Western blotting
and immunofluorescence showed significant changes in expression levels of EMT marker proteins, E-cadherin and vimentin, are observed in
NCI-H1299 cells after GC7 treatment. (E) The migration and (F) invasion capabilities are weaker in NCI-H1299 cells after GC7 treatment.
Figure 5 GC7 pre-treatment prevents A549 cells from undergoing EMT after TGF-β1 stimulation. (A) morphology (B) Western blotting
(C) immunofluorescence (D) wound-healing assay (E) Transwell-Matrigel invasion assay.
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Figure 6 GC7 reverses EMT in NCI-H1299 cells via eIF5A-2 regulation. (A) Western blotting (B) immunofluorescence (C) wound-healing assay
(D) Transwell-Matrigel invasion assay.
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vation. Our study found that mesenchymal NCI-H1299
cells changed to epithelial phenotype when co-treated with
GC7; furthermore, in agreement with other reports, we
found that GC7 not only increased NCI-H1299 sensitivity
to cisplatin cells but also reduced the migration and inva-
sion capabilities of NCI-H1299 cells.
TGF-β signaling plays an important role in the EMT
process through regulation of Snail, SOX2, SOX4 and
ID1 [34-36] and has been reported to stimulate NSCLC
cells to undergo EMT [29,37,38]. In previous study we
found that after exposure to TGF-β1, epithelial A549
cells changed to mesenchymal phenotype, developing a
mesenchymal appearance, higher levels of vimentin,
lower levels of E-cadherin and stronger migration and
invasion capabilities [39]. In this study, we mainly inves-
tigate GC7 whether can be reversed this effect, and the
result showed that EMT could be prevented if A549 cells
were pre-treated with GC7. This suggested that eIF5A-2
might be an upstream factor regulating EMT and thereby
plays an important role in EMT phenotype changes.
Conclusion
In conclusion, our study found that GC7 changed NCI-
H1299 cells from mesenchymal phenotype to epithelial
phenotype and enhanced their sensitivity to cisplatin via
inhibition of eIF5A-2, whereas GC7 prevented epithelial
A549 cells from undergoing EMT changes via inhibition
of eIF5A-2. This suggests that eIF5A-2 may be a key
regulatory factor in EMT and drug resistance in NSCLC.
As such, inhibition of eIF5A-2 could enhance NSCLC
sensitivity to chemotherapeutics, prevent or reverseEMT, and reduce the migration and invasion capabilities
of NSCLC cells. These findings not only support the use
of EIF5A2 as an adverse prognostic marker in NSCLC
patients, but may also offer a novel approach for the
treatment of NSCLC.Additional files
Additional file 1: Figure S1. Evaluate the possible synergism between
GC7 and cisplatin on the growth inhibition of NSCLC (A) NCI-H1299 (B) A549.
Additional file 2: Figure S2. Fluorogram of SDS-PAGE separated
hypusinated–eIF5A1/eIF5A2 protein (Hypusined eIF5A isoform) in
NCI-H1299 and A549 cells protein lysates after 48 h incubation with or
without GC7 (20 μM) in the presence of [1,8-3H]-spermidine.
Additional file 3: Figure S3. (A-B) Comparing changes in cisplatin
sensitivity in A549 and NCI-H1299 NSCLC cells after treatment with
eIF5A-1 siRNA alone or combined with GC7. (C) Western blotting showing
eIF5A-1 expression in A549 and NCI-1299 cells. (D) eIF5A-1 siRNA inhibits
eIF5A-2 in both A549 and NCI-H1299 cells. (E) The effects of GC7 and cisplatin
on the expression of the two isoforms of eIF-5A in the NSCLC cell lines.Competing interests
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